𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase II study of 5-fluorouracil, leucovorin, and interferon-α in the treatment of patients with metastatic or recurrent gastric carcinoma : An Eastern Cooperative Oncology Group study (E5292)

✍ Scribed by Gary R. Hudes; Stuart Lipsitz; Jean Grem; Mary Morrisey; Louis Weiner; John W. Kugler; Al Benson III

Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
68 KB
Volume
85
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Chemotherapy has a limited impact on adenocarcinoma of the stomach. Although biochemical modulation of 5-fluorouracil (5-FU) by leucovorin (LV) and interferon-␣ (IFN-␣) has improved the outcomes of patients with metastatic colorectal carcinoma compared with 5-FU alone, this approach has not been extensively evaluated in the treatment of advanced gastric carcinoma.

📜 SIMILAR VOLUMES

A phase II trial of interferon-α and 5-f
A phase II trial of interferon-α and 5-fluorouracil in patients with advanced renal cell carcinoma: A Southwest Oncology Group study
✍ Laurence Elias; Brent A. Blumenstein; Julie Kish; Robert C. Flanigan; James L. W 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB 👁 1 views

## BACKGROUND. Renal cell carcinoma is a common neoplasm that is often refractory to treatment. It is occasionally responsive to immunoniodulating agents including interferon-a, which enhances the effects of 5-fluorouracil upon cells. Combinations of these two drugs have been most frequently tested

Phase II study of 5-fluorouracil and fol
Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer: A Southwest Oncology Group study
✍ Giuseppe Colucci 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

n the article published in Cancer entitled "Phase I1 study of 5-fluoro-I uracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group Study,"' the authors erroneously quoted the results of our study and we request a correction. In the results of our

A randomized Phase II trial of echinomyc
A randomized Phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma : An Eastern Cooperative Oncology Group Study (E1587)
✍ Alex Y. Chang; KyungMann Kim; Hélène Boucher; Philip Bonomi; James A. Stewart; D 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 1 views

## Background: Patients with metastatic nonsmall cell lung carcinoma (nsclc) usually have a poor prognosis. a chemotherapy regimen containing cisplatin is commonly used for symptom palliation. echinomycin is a potent bifunctional intercalator of double-strand dna; trimetrexate is a new derivative o

13-cis-retinoic acid in the treatment of
13-cis-retinoic acid in the treatment of elderly patients with acute myeloid leukemia. A phase II pilot study of the eastern cooperative oncology group
✍ Zachary B. Kramer; Laszlo Boros; Peter H. Wiernik; Janet Andersen; John M. Benne 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB 👁 1 views

The management of acute myeloid leukemia in the elderly (65 years and older) is unsatisfactory because of poor patient tolerance of standard myeloablative chemotherapy. The authors conducted a Phase II study to evaluate the effectiveness and toxicity of 13-cis-retinoic acid (CRA) in the therapy of e